Primary care
AAFP endorses updated migraine prevention guideline
The guideline recommends preventive treatment for adults with four or more migraine days per month, four or more moderate-to-severe headache days per month, or substantial migraine-related disability.
The American Academy of Family Physicians has endorsed an updated guideline on pharmacologic migraine prevention for adults, developed by the American Academy of Neurology and the American Headache Society. AAFP said the update reviews established and newer preventive medications and incorporates evidence published since 2012.
The guideline recommends offering preventive treatment to patients with four or more migraine days per month, four or more moderate-to-severe headache days per month, or substantial migraine-related disability. It advises clinicians to consider a patient’s medical history, potential side effects, cost and preferences when choosing a medication.
The endorsement is part of a broader collaboration among the AAFP, AAN and AHS to improve headache care in primary care. The organizations plan to explore clinical guidance, educational materials and decision-making tools, including clearer guidance on referrals and shared care with neurologists and headache specialists.
